propranolol and Retrolental Fibroplasia studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research Excerpts

Excerpt	Relevance	Reference
"Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely."	9.24	Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. ( Agosti, M; Araimo, G; Bagnoli, P; Berti, E; Calvani, AM; Cavallaro, G; Cortinovis, I; Cristofori, G; Dal Monte, M; Della Bona, ML; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Fumagalli, M; la Marca, G; Milani, S; Mosca, F; Osnaghi, S; Padrini, L; Pasqualetti, R; Pugi, A; Tomasini, B; Vanni, M, 2017)
"To assess the effect of oral propranolol on the progression of early stages of retinopathy of prematurity (ROP) in very low birth weight (VLBW) infants."	9.22	Oral propranolol in early stages of retinopathy of prematurity. ( Bancalari, A; Lazcano, C; Muñoz, T; Parada, R; Peña, R; Schade, R, 2016)
"To evaluate safety and efficacy of oral propranolol administration in preterm newborns affected by an early phase of retinopathy of prematurity (ROP)."	9.17	Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. ( Araimo, G; Bagnoli, P; Cavallaro, G; Cristofori, G; Dal Monte, M; Della Bona, ML; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Furlanetto, S; la Marca, G; La Torre, A; Mosca, F; Osnaghi, S; Tinelli, F, 2013)
"Propranolol can reduce the formation of abnormal retinal neovascularization in oxygen-induced retinopathy (OIR) models, and reduce leaking, tortuous, and abnormally expanding retinal blood vessels."	8.31	Propranolol ameliorates retinopathy of prematurity in mice by downregulating HIF-1α via the PI3K/Akt/ERK pathway. ( Ding, Y; Liu, L; Liu, Y; Su, S; Wang, Y; Yang, G; Zhang, J; Zou, P, 2023)
" Establishing the optimal dosage and treatment schedule is to date a crucial issue."	6.84	Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. ( Agosti, M; Araimo, G; Aversa, S; Bagnoli, P; Berti, E; Borsari, G; Bossi, A; Bozzetti, V; Buonocore, G; Calvani, AM; Cavallaro, G; Cavallotti, B; Chirico, G; Cortinovis, I; Dal Monte, M; De Angelis, C; Donati, S; Donzelli, G; Filippi, L; Forni, G; Fortunato, P; la Marca, G; Milani, S; Mosca, F; Nascimbeni, G; Osnaghi, S; Padrini, L; Pasqualetti, R; Pugi, A; Regiroli, G; Tagliabue, P; Tomasini, B; Vanni, M; Villamor, E, 2017)
"Oral propranolol has improved the treatment of infantile hemangiomas, and a pediatric oral solution of propranolol has recently been licensed in the USA and Europe."	6.80	Oral Propranolol: A New Treatment for Infants with Retinopathy of Prematurity? ( Bassler, D; Bührer, C, 2015)
" The objective of this research is highly ambitious: to find a treatment simple, inexpensive, well tolerated and with few adverse effects, able to counteract one of the major complications of the prematurity."	6.75	Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. ( Araimo, G; Bagnoli, P; Benedetti, V; Bilia, AR; Cavallaro, G; Cioni, G; Cristofori, G; Dal Monte, M; Daniotti, M; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Furlanetto, S; Isacchi, B; la Marca, G; La Torre, A; Malvagia, S; Mosca, F; Osnaghi, S; Pollazzi, L; Ramenghi, L; Ristori, C; Tinelli, F, 2010)
"Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely."	5.24	Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. ( Agosti, M; Araimo, G; Bagnoli, P; Berti, E; Calvani, AM; Cavallaro, G; Cortinovis, I; Cristofori, G; Dal Monte, M; Della Bona, ML; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Fumagalli, M; la Marca, G; Milani, S; Mosca, F; Osnaghi, S; Padrini, L; Pasqualetti, R; Pugi, A; Tomasini, B; Vanni, M, 2017)
"To assess the effect of oral propranolol on the progression of early stages of retinopathy of prematurity (ROP) in very low birth weight (VLBW) infants."	5.22	Oral propranolol in early stages of retinopathy of prematurity. ( Bancalari, A; Lazcano, C; Muñoz, T; Parada, R; Peña, R; Schade, R, 2016)
"To evaluate safety and efficacy of oral propranolol administration in preterm newborns affected by an early phase of retinopathy of prematurity (ROP)."	5.17	Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. ( Araimo, G; Bagnoli, P; Cavallaro, G; Cristofori, G; Dal Monte, M; Della Bona, ML; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Furlanetto, S; la Marca, G; La Torre, A; Mosca, F; Osnaghi, S; Tinelli, F, 2013)
"The serendipitous demonstration that the nonselective β-adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-adrenergic system in angiogenic processes."	4.91	Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system. ( Bagnoli, P; Casini, G; Dal Monte, M; Daniotti, M; Filippi, L; Sereni, F, 2015)
"Propranolol can reduce the formation of abnormal retinal neovascularization in oxygen-induced retinopathy (OIR) models, and reduce leaking, tortuous, and abnormally expanding retinal blood vessels."	4.31	Propranolol ameliorates retinopathy of prematurity in mice by downregulating HIF-1α via the PI3K/Akt/ERK pathway. ( Ding, Y; Liu, L; Liu, Y; Su, S; Wang, Y; Yang, G; Zhang, J; Zou, P, 2023)
" Propranolol, a nonselective β-adrenergic receptor blocker, was reported to protect against pathologic retinal neovascularization in a mouse model of oxygen-induced retinopathy (OIR)."	3.78	Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. ( Chen, J; Hatton, CJ; Hellstrom, A; Hurst, CG; Joyal, JS; Juan, AM; Pei, DT; Smith, LE; Stahl, A; Xu, D, 2012)
" Establishing the optimal dosage and treatment schedule is to date a crucial issue."	2.84	Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. ( Agosti, M; Araimo, G; Aversa, S; Bagnoli, P; Berti, E; Borsari, G; Bossi, A; Bozzetti, V; Buonocore, G; Calvani, AM; Cavallaro, G; Cavallotti, B; Chirico, G; Cortinovis, I; Dal Monte, M; De Angelis, C; Donati, S; Donzelli, G; Filippi, L; Forni, G; Fortunato, P; la Marca, G; Milani, S; Mosca, F; Nascimbeni, G; Osnaghi, S; Padrini, L; Pasqualetti, R; Pugi, A; Regiroli, G; Tagliabue, P; Tomasini, B; Vanni, M; Villamor, E, 2017)
"Oral propranolol has improved the treatment of infantile hemangiomas, and a pediatric oral solution of propranolol has recently been licensed in the USA and Europe."	2.80	Oral Propranolol: A New Treatment for Infants with Retinopathy of Prematurity? ( Bassler, D; Bührer, C, 2015)
" The objective of this research is highly ambitious: to find a treatment simple, inexpensive, well tolerated and with few adverse effects, able to counteract one of the major complications of the prematurity."	2.75	Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. ( Araimo, G; Bagnoli, P; Benedetti, V; Bilia, AR; Cavallaro, G; Cioni, G; Cristofori, G; Dal Monte, M; Daniotti, M; Donzelli, G; Filippi, L; Fiorini, P; Fortunato, P; Furlanetto, S; Isacchi, B; la Marca, G; La Torre, A; Malvagia, S; Mosca, F; Osnaghi, S; Pollazzi, L; Ramenghi, L; Ristori, C; Tinelli, F, 2010)
" Although meta-analysis did not indicate a significant effect of beta-blockers on arterial hypotension or bradycardia, propranolol dosage in one study was reduced by 50% in infants of less than 26 weeks' gestational age due to severe hypotension, bradycardia, and apnoea in several participants."	2.58	Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. ( Jost, K; Kaempfen, S; Neumann, RP; Schulzke, SM, 2018)
"Propranolol was administered subcutaneously and picropodophyllin (PPP) intraperitoneally."	1.37	Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. ( Bagnoli, P; Cammalleri, M; Dal Monte, M; Filippi, L; Fiorini, P; Fortunato, P; la Marca, G; Martini, D; Ristori, C, 2011)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	22 (84.62)	24.3611
2020's	4 (15.38)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Newborn With Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)[NCT02504944]	Phase 2	98 participants (Actual)	Interventional	2015-07-31	Completed
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity[NCT03083431]	Phase 2	276 participants (Anticipated)	Interventional	2022-09-22	Recruiting
Safety and Efficacy of Propranolol Eye Drops in Newborns With Retinopathy of Premature (DROP-PROP)[NCT02014454]	Phase 2	23 participants (Actual)	Interventional	2013-11-30	Completed
Safety and Efficacy of Propranolol Treatment in Newborns With Retinopathy of Prematurity:a Prospective Cohort Study[NCT03038295]	Phase 2	100 participants (Anticipated)	Interventional	2017-03-31	Not yet recruiting
Safety and Efficacy of Treatment With Propranolol in Newborns With Retinopathy of Prematurity: a Pilot Study[NCT01079715]	Phase 2/Phase 3	52 participants (Actual)	Interventional	2010-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis. Journal of perinatology : official journal of the California Perinatal Association, 2019, Volume: 39, Issue:12 Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Humans; Infant, Newborn; Inf	2019
Update in the Treatment of Retinopathy of Prematurity. American journal of perinatology, 2022, Volume: 39, Issue:1 Topics: Adrenergic beta-Antagonists; Bevacizumab; Disease Progression; Humans; Infant, Newborn; Infant, Prem	2022
[Retinopathy of the premature: Update in screening and treatment]. Revista chilena de pediatria, 2020, Volume: 91, Issue:1 Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Humans; Infant, Newborn; Infant, Premature;	2020
Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. The Cochrane database of systematic reviews, 2018, 03-02, Volume: 3 Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cryotherapy; Disease Progression; Humans; Infa	2018
Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system. Medicinal research reviews, 2015, Volume: 35, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Cell Line, Tumor; Child, Preschool; Hemangioma; Humans; Hypoxi	2015

Article	Year
Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. BMC pediatrics, 2017, Jul-14, Volume: 17, Issue:1 Topics: Administration, Topical; Adrenergic beta-Antagonists; Clinical Protocols; Female; Humans; Infant, Ne	2017
Short-term Refractive Effects of Propranolol Hydrochloride Prophylaxis on Retinopathy of Prematurity in Very Preterm Newborns. Current eye research, 2018, Volume: 43, Issue:2 Topics: Adrenergic beta-Antagonists; Anthropometry; Double-Blind Method; Female; Gestational Age; Humans; In	2018
Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial. BMJ open, 2018, 07-06, Volume: 8, Issue:7 Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Double-Blind Method; Gestati	2018
The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: Which newborn and when? International ophthalmology, 2019, Volume: 39, Issue:9 Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me	2019
Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study. Archives of disease in childhood, 2013, Volume: 98, Issue:7 Topics: Double-Blind Method; Humans; Infant, Newborn; Pilot Projects; Propranolol; Prospective Studies; Reti	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. The Journal of pediatrics, 2013, Volume: 163, Issue:6 Topics: Adrenergic beta-Antagonists; Female; Humans; Infant, Premature; Male; Pilot Projects; Propranolol; R	2013
Oral Propranolol: A New Treatment for Infants with Retinopathy of Prematurity? Neonatology, 2015, Volume: 108, Issue:1 Topics: Female; Humans; Infant; Infant, Extremely Premature; Infant, Newborn; Israel; Italy; Male; Pilot Pro	2015
Oral propranolol in early stages of retinopathy of prematurity. Journal of perinatal medicine, 2016, Jul-01, Volume: 44, Issue:5 Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Bevacizumab; Disease Pro	2016
Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. Pediatric research, 2017, Volume: 81, Issue:2 Topics: Administration, Ophthalmic; Administration, Oral; Administration, Topical; Disease Progression; Fema	2017
Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC pediatrics, 2010, Nov-18, Volume: 10 Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-	2010

Article	Year
Propranolol ameliorates retinopathy of prematurity in mice by downregulating HIF-1α via the PI3K/Akt/ERK pathway. Pediatric research, 2023, Volume: 93, Issue:5 Topics: Animals; Disease Models, Animal; Endothelial Cells; Humans; Infant, Newborn; MAP Kinase Signaling Sy	2023
Treating infants with 0.2% propranolol eye micro-drops drastically reduced the progression of retinopathy of prematurity. Acta paediatrica (Oslo, Norway : 1992), 2023, Volume: 112, Issue:9 Topics: Disease Progression; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; In	2023
Propranolol increases vascular permeability through pericyte apoptosis and exacerbates oxygen-induced retinopathy. Biochemical and biophysical research communications, 2018, 09-18, Volume: 503, Issue:4 Topics: Animals; Animals, Newborn; Apoptosis; Capillary Permeability; Coculture Techniques; Disease Models,	2018
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Experimental eye research, 2013, Volume: 111 Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Infa	2013
[Propranolol as a possible new pharmacologic treatment of retinopathy of prematurity]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2015, Volume: 53, Issue:7 Topics: Humans; Infant, Newborn; Infant, Premature; Propranolol; Retinopathy of Prematurity	2015
The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index. Current eye research, 2017, Volume: 42, Issue:1 Topics: Adrenergic beta-Antagonists; Blood Platelets; Female; Gestational Age; Humans; Infant; Infant, Newbo	2017
Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Investigative ophthalmology & visual science, 2011, Jan-05, Volume: 52, Issue:1 Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Animals; Animals, Newborn; Blood-Retinal Barri	2011
On the use of antiangiogenetic medications for retinopathy of prematurity. Acta paediatrica (Oslo, Norway : 1992), 2011, Volume: 100, Issue:8 Topics: Adrenergic beta-1 Receptor Antagonists; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized;	2011
Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Investigative ophthalmology & visual science, 2012, May-17, Volume: 53, Issue:6 Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiopoietin-1; Angiopoietin-2; Animals; Animals,	2012
Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? Investigative ophthalmology & visual science, 2012, Oct-30, Volume: 53, Issue:11 Topics: Adrenergic beta-Antagonists; Animals; Humans; Mice; Propranolol; Retinal Neovascularization; Retinop	2012
Author response: Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? Investigative ophthalmology & visual science, 2012, Nov-19, Volume: 53, Issue:12 Topics: Adrenergic beta-Antagonists; Animals; Humans; Mice; Propranolol; Retinal Neovascularization; Retinop	2012

propranolol and Retrolental Fibroplasia

Research Excerpts

Research

Studies (26)

Authors

Clinical Trials (5)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Su, S	1
Zou, P	1
Yang, G	1
Wang, Y	2
Liu, L	1
Liu, Y	1
Zhang, J	1
Ding, Y	1
Scaramuzzo, RT	1
Bagnoli, P	9
Dal Monte, M	9
Cammalleri, M	2
Pini, A	1
Ballini, S	1
Bendinelli, A	1
Desideri, I	1
Ciantelli, M	1
Filippi, L	9
Stritzke, A	1
Kabra, N	1
Kaur, S	1
Robertson, HL	1
Lodha, A	1
Bancalari, A	2
Schade, R	3
Bancalari M, A	1
Cavallaro, G	4
Berti, E	2
Padrini, L	2
Araimo, G	4
Regiroli, G	1
Bozzetti, V	1
De Angelis, C	1
Tagliabue, P	1
Tomasini, B	2
Buonocore, G	1
Agosti, M	2
Bossi, A	1
Chirico, G	1
Aversa, S	1
Pasqualetti, R	2
Fortunato, P	5
Osnaghi, S	4
Cavallotti, B	1
Vanni, M	2
Borsari, G	1
Donati, S	1
Nascimbeni, G	1
la Marca, G	6
Forni, G	1
Milani, S	2
Cortinovis, I	2
Calvani, AM	2
Pugi, A	2
Villamor, E	1
Donzelli, G	4
Mosca, F	4
Korkmaz, L	3
Karaca, C	2
Akin, MA	2
Bastug, O	2
Sahiner, M	1
Ozdemir, A	2
Gunes, T	2
Ozturk, MA	3
Kurtoglu, S	2
Kaempfen, S	1
Neumann, RP	1
Jost, K	1
Schulzke, SM	1
Bührer, C	2
Erdeve, Ö	1
Bassler, D	2
Bar-Oz, B	2
Yun, JH	1
Koh, YJ	1
Jeong, HS	1
Lee, DH	1
Lee, EH	1
Cho, CH	1
Casini, G	2
Isacchi, B	2
Makhoul, IR	1
Peleg, O	1
Miller, B	1
Kochavi, O	1
Mechoulam, H	1
Mezer, E	1
Ulanovsky, I	1
Smolkin, T	1
Yahalom, C	1
Khoury, A	1
Lorber, A	1
Nir, A	1
Blazer, S	1
Fiorini, P	4
Tinelli, F	2
Cristofori, G	3
Della Bona, ML	2
La Torre, A	2
Furlanetto, S	2
Daniotti, M	2
Sereni, F	1
Huang, X	1
Yang, Z	1
Muñoz, T	1
Lazcano, C	1
Parada, R	1
Peña, R	1
Korkut, S	1
Fumagalli, M	1
Ristori, C	2
Martini, D	1
Benedetti, V	1
Ramenghi, L	1
Pollazzi, L	1
Malvagia, S	1
Bilia, AR	1
Cioni, G	1
Hård, AL	1
Hellström, A	3
Chen, J	2
Joyal, JS	1
Hatton, CJ	1
Juan, AM	1
Pei, DT	1
Hurst, CG	1
Xu, D	1
Stahl, A	1
Smith, LE	2